However, Sohan et al. revealed that, after RTX treatment, Tfh cells and TGF-β-producing cells remained in the blood of IgG4-RD patients, suggesting that these cells might be risk factors for incomplete resolution of the inflammatory process [9]. The gene discussed is TGFB1; the disease is immunoglobulin G4-related sclerosing disease.